Wednesday, November 25, 2009, 10:57am EST - Canadian Markets close in 5 hours and 3 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Nektar Therapeutics (NKTR)

At 10:41 EST: 8.83 USD  Up 0.13 (1.49%)  
MORE ON NKTR
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Nektar Therapeutics (NasdaqNM:NKTR) Delayed quote dataEdit
Last Trade: 8.83 USD
Trade Time: 10:41AM EST
Change: Up 0.13 (1.49%)
Prev Close: 8.70
Open: 8.69
Bid: 8.85 x 300
Ask: 8.87 x 200
1y Target Est: 10.55
Day's Range: 8.66 - 8.97
52wk Range: 3.90 - 10.64
Volume: 80,728
Avg Vol (3m): 759,258
Market Cap: 822.93M
P/E (ttm): N/A
EPS (ttm): -1.21
Div & Yield: N/A (N/A%)
Nektar Therapeutics (NKTR)
1d  5d  3m  6m  1y  2y  5y  max 
 Add NKTR to Portfolio   Download Data

HEADLINES
Abbott: Brave or Stupid?
at Motley Fool (Fri, Nov 13)
AstraZeneca Beats, Raises
Zacks.com (Fri, Nov 13)
NEKTAR THERAPEUTICS Financials
EDGAR Online Financials (Tue, Nov 10)
New Star Analyst Rankings for Nektar Therapeutics
StarMine (Thu, Nov 5)
NEKTAR THERAPEUTICS Files SEC form 10-Q, Quarterly Report
EDGAR Online (Thu, Nov 5)
Nektar Therapeutics Financial Results Call scheduled for 5:00 pm ET today
CCBN (Wed, Nov 4)
NEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
EDGAR Online (Wed, Nov 4)
Nektar Therapeutics Reports Third Quarter 2009 Financial Results
PRNewswire (Wed, Nov 4)
Q3 2009 Nektar Therapeutics Earnings Release - Time Not Supplied
CCBN (Wed, Nov 4)
Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
PRNewswire (Thu, Oct 29)
Nektar Completes Enrollment Ahead of Schedule in Phase 2 Clinical Trial Evaluating NKTR-102 in Patients with Platinum-Resistant Ovarian Cancer
PRNewswire (Wed, Oct 28)
More Headlines for NKTR...

ANALYST
EPS Est (next year) (Dec-07) : N/A
EPS Est (in 2 years) (Dec-08) : N/A
Avg Rec (current)*: 2.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News Canadian Indices